Table 1.

Clinicopathological characteristics at baseline and treatment strategies

	BM cohort (N = 12) N(%)	LM cohort (N = 16) N(%)
Age
Median (IQR)	60 (52–72)	58 (53–62)
Gender
Female	5 (41.7)	10 (62.5)
Male	7 (58.3)	6 (37.5)
ECOG-PS
0–1	7 (58.3)	2 (12.5)
2–3	5 (41.7)	14 (87.5)
Clinical stage at diagnosis
IV	7 (58.3)	9 (56.3)
I-III	5 (41.7)	7 (43.8)
EGFR status at baseline
Exon 19del	5 (41.7)	7 (43.8)
Exon21 L858R	7 (58.3)	6 (37.5)
Other EGFR mutations	0 (0.0)	3 (18.8)
EGFR status in CSF
EGFR mutations available	–	4 (25.0)
Negative	–	1 (6.3)
Unknown	–	11 (68.8)
CNS-related symptoms
Presence	3 (25.0)	15 (93.8)
Absence	9 (75.0)	1 (6.3)
EGFR status prior to furmonertinib
Unknown/negative	7 (58.3)	10 (62.5)
T790M mutations	3 (25.0)	1 (6.3)
EGFR sensitive mutations	2 (16.7)	5 (31.3)
Previous lines of systemic therapy
0–1	4 (33.3)	11 (68.8)
2–3	8 (66.7)	5 (31.3)
Rechallenge of 3rd generation TKI
Yes	9 (75.0)	10 (62.5)
No	3 (25.0)	6 (37.5)
Treatment between 3rd generation TKI and furmonertinib
Other TKI	1 (11.1)	2 (20.0)
Chemotherapy	5 (55.6)	3 (30.0)
No treatment	3 (33.3)	5 (50.0)
Pre-treated/concurrent with RT
Yes	10 (83.3)	6 (37.5)
No	2 (16.7)	10 (62.5)
Treatment strategies
Furmonertinib monotherapy	6 (50.0)	11 (68.8)
Furmonertinib+anti-angiogenic agent	6 (50.0)	5 (31.3)
Intrathecal injection
Yes	–	9 (56.3)
No	–	7 (43.8)
Regimens for intrathecal injection
Pemetrexed	–	5 (55.6)
MTX	–	4 (44.4)

The percentages might not equal 100% on account of rounding

n number, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, CSF cerebral spinal fluid, CNS central nervous system, TKI tyrosine kinase inhibior, RT radiotherapy